指南与共识心律失常冠心病血脂与心血管预防

2018 EHRA实用指南:非维生素K拮抗剂口服抗凝药在房颤患者中的应用

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
指南 / 共识 · Eur Heart J · 2018-01-01

该指南为EHRA实用指南的第二次更新,针对房颤患者使用NOACs的20个具体临床场景给出实践答案。NOACs已成为新启动抗凝患者的首选,但特定临床情况下的优化使用仍存疑问,指南旨在统一信息传达。

要点

  • NOACs是房颤卒中预防中VKAs的替代选择,尤其适用于新启动抗凝者。
  • 指南涵盖20个临床场景,包括启动随访、依从性、转换、药物相互作用等。
  • 针对肾功能不全、冠心病、出血管理、围手术期等特殊情况提供实践指导。

核心结论

  • NOACs已成为房颤患者卒中预防的首选抗凝选择,尤其在新启动抗凝患者中。
  • EHRA针对20个具体临床场景制定了实践答案,以统一NOACs使用信息。
  • 尽管NOACs使用日益普遍,特定临床情况下的优化使用仍存在未解决问题。

研究设计与样本

  • 本文为EHRA实用指南的第二次更新,前版分别于2013年和2015年发布。
  • 写作组基于现有证据,识别了20个具体临床场景并制定实践答案。

关键数值与推荐

  • 指南涵盖20个主题:NOACs适用性、启动与随访方案、依从性、抗凝方案转换、药代动力学与药物相互作用、慢性肾病或晚期肝病、抗凝效果测量、血浆水平检测、剂量错误处理、疑似过量无出血、出血管理、计划侵入性操作/手术/消融、紧急手术、房颤合并冠心病、避免跨适应症剂量混淆、NOAC治疗患者的心脏复律、急性卒中、特殊情况、合并恶性肿瘤抗凝、优化VKA剂量调整。
  • 额外信息及不同语言抗凝卡片可从EHRA网站(www.NOACforAF.eu)下载。

临床怎么用

  • 临床医生可参照20个场景的实践答案优化NOACs在房颤患者中的使用。
  • 针对肾功能不全、冠心病、围手术期等特殊情况,指南提供了具体处理建议。
  • 可通过EHRA网站获取抗凝卡片等工具辅助患者管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group identified 20 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 20 topics are as follows i.e., (1) Eligibility for NOACs; (2) Practical start-up and follow-up scheme for patients on NOACs; (3) Ensuring adherence to prescribed oral anticoagulant intake; (4) Switching between anticoagulant regimens; (5) Pharmacokinetics and drug-drug interactions of NOACs; (6) NOACs in patients with chronic kidney or advanced liver disease; (7) How to measure the anticoagulant effect of NOACs; (8) NOAC plasma level measurement: rare indications, precautions, and potential pitfalls; (9) How to deal with dosing errors; (10) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding; (11) Management of bleeding under NOAC therapy; (12) Patients undergoing a planned invasive procedure, surgery or ablation; (13) Patients requiring an urgent surgical intervention; (14) Patients with AF and coronary artery disease; (15) Avoiding confusion with NOAC dosing across indications; (16) Cardioversion in a NOAC-treated patient; (17) AF patients presenting with acute stroke while on NOACs; (18) NOACs in special situations; (19) Anticoagulation in AF patients with a malignancy; and (20) Optimizing dose adjustments of VKA. Additional information and downloads of the text and anticoagulation cards in different languages can be found on an EHRA website (www.NOACforAF.eu).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018. PMID: 29562325. doi:10.1093/eurheartj/ehy136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。